Media stories about ACADIA Pharmaceuticals (NASDAQ:ACAD) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ACADIA Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.680560346296 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

Shares of ACADIA Pharmaceuticals (NASDAQ ACAD) opened at $27.78 on Friday. ACADIA Pharmaceuticals has a fifty-two week low of $25.06 and a fifty-two week high of $41.20. The stock has a market cap of $3,400.00, a P/E ratio of -11.29 and a beta of 3.79.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.10. ACADIA Pharmaceuticals had a negative net margin of 320.71% and a negative return on equity of 67.68%. The company had revenue of $35.58 million for the quarter, compared to the consensus estimate of $32.03 million. During the same period last year, the company earned ($0.61) earnings per share. The firm’s revenue was up 571.3% compared to the same quarter last year. equities research analysts expect that ACADIA Pharmaceuticals will post -2.41 EPS for the current fiscal year.

ACAD has been the topic of a number of research reports. Jefferies Group reaffirmed a “buy” rating and issued a $47.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 12th. JPMorgan Chase & Co. set a $50.00 price objective on shares of ACADIA Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 5th. Leerink Swann reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Monday, October 9th. Zacks Investment Research downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 16th. Finally, JMP Securities lifted their price objective on shares of ACADIA Pharmaceuticals from $47.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, October 5th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company’s stock. ACADIA Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $48.86.

In related news, Director Laura Brege sold 25,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $30.06, for a total transaction of $751,500.00. Following the transaction, the director now directly owns 15,000 shares in the company, valued at $450,900. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Glenn Baity sold 74,321 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $30.14, for a total transaction of $2,240,034.94. The disclosure for this sale can be found here. 22.25% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2018/01/18/acadia-pharmaceuticals-acad-earns-daily-media-impact-rating-of-0-15.html.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.